An analyst from Piper Sandler maintained Viatris (NASDAQ: VTRS) at 'neutral' with a price target of $11.00 from a prior price target of %currency%%price%. Prior to this rating, Viatris had...
NEW YORK - Viatris Inc (NASDAQ:VTRS). and Theravance Biopharma (NASDAQ:TBPH) have announced successful results from a Phase III trial for YUPELRI (revefenacin) conducted in China, involving...
Viatris Inc. (VTRS), a global healthcare company, and Theravance Biopharma, Inc. (TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical...
Viatris reported robust Q3 2023 results, with operational revenue growth of approximately 1% year-over-year, adjusted EBITDA of $1.36 billion, and free cash flow of $738 million. The company...
Investing.com - Viatris (NASDAQ: VTRS) reported third quarter EPS of $0.27, $0.47 worse than the analyst estimate of $0.74. Revenue for the quarter came in at $3.94B versus the consensus...
(Updated - October 23, 2023 6:11 AM EDT) BofA Securities analysts downgraded Viatris (VTRS) from Neutral to Underperform with a price target of $9.00 (from $13.00).The analysts comment "We...
An analyst from UBS maintained Viatris (NASDAQ: VTRS) at 'neutral' with a price target of $11.00 from a prior price target of %currency%%price%. Prior to this rating, Viatris had 2 buy...
Novo Nordisk (NYSE:NVO) saw a nearly 1% rise in its stock price today after the U.S. Patent Office tribunal rejected challenges to two critical patents for its drugs Wegovy and Ozempic....
Nimmagadda Prasad, the founder of Matrix Laboratories, has bought back the active pharmaceutical ingredients (API) business he sold to Mylan NV (now Viatris) in 2006. The acquisition was...
New Delhi, Oct 2 (AINS) Viatris (formerly known as Mylan Inc (NASDAQ:VTRS)) has finalised two deals in India to divest its API (active pharmaceutical ingredients) and women's healthcare...
Viatris Inc. (VTRS), a global healthcare company, today announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered...
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and...
Viatris Inc. (VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5...
Investing.com - Viatris (NASDAQ: VTRS) reported second quarter EPS of $0.22, $0.49 worse than the analyst estimate of $0.71. Revenue for the quarter came in at $3.9B versus the consensus...
Viatris Inc. (VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company, today announced that the U.S. Food and...
Viatris Inc. (VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the...
Here is your Pro Recap of the biggest analyst cuts you may have missed since Friday: downgrades at |Tesla, Alphabet, Celanese , and Viatris.InvestingPro subscribers got this news first....
An analyst from Barclays downgraded Viatris (NASDAQ: VTRS) from 'equalweight' to 'underweight' with a price target of $11.00. Prior to this rating, Viatris had 3 buy ratings, 7 hold...
Viatris Inc. (VTRS), a global healthcare company, today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris' newest member of its...
Investing.com - Viatris (NASDAQ: VTRS) reported first quarter EPS of $0.19, $0.50 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $3.73B versus the consensus...
A Barclays analyst downgraded Viatris (NASDAQ: VTRS) from Overweight to Equalweight with a price target of $11.00 from a prior price target of %currency%%price%. Prior to this rating,...
Viatris Inc. (VTRS) announced that the U.S. District Court for the Southern District of New York has dismissed all claims against the Company in their entirety and granted its motion for...
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid...
Viatris Inc. (VTRS), a global healthcare company, today announced that as it prepares to enter Phase 2 of its previously announced strategic plan in 2024, Scott A. Smith has been appointed...
Viatris Inc (VTRS) reported Q4 EPS of $0.83, which may not compare to the analyst estimate of $0.72. Revenue for the quarter came in at $3.87 billion versus the consensus estimate of $3.98...
By Sarina Isaacs, Davit Kirakosyan, Reuters Investing.com - Here are the hottest pieces of M&A news from the past week, as covered first on InvestingPro+. in a rapid reversal, Binance...
By Liz Moyer Investing.com -- Stocks were rising as investors awaited the outcome of the midterm elections, and the answer to which party will control Congress. Here are the midday movers...
Viatris Inc (VTRS) reported Q3 EPS of $0.29, $0.55 worse than the analyst estimate of $0.84. Revenue for the quarter came in at $4.07 billion versus the consensus estimate of $4.14...
Viatris Inc (VTRS) reported Q2 EPS of $0.88, $0.05 better than the analyst estimate of $0.83. Revenue for the quarter came in at $4.12 billion versus the consensus estimate of $4.18...
Investing.com – U.S. equities were lower at the close on Monday, as losses in the Oil & Gas, Technology and Basic Materials sectors propelled shares lower. At the close in NYSE, the Dow...
Viatris Inc (VTRS) reported Q1 EPS of $0.93, $0.09 better than the analyst estimate of $0.84. Revenue for the quarter came in at $4.18 billion versus the consensus estimate of $4.27...
Investing.com – U.S. equities were lower at the close on Monday, as losses in the Telecoms, Utilities and Oil & Gas sectors propelled shares lower. At the close in NYSE, the Dow Jones...
By Malvika Gurung Investing.com -- Shares of the pharmaceutical major Biocon (NS:BION) tanked 7.86% to Rs 363.55 apiece at 10:31 am on Monday, after the company’s subsidiary Biocon...
By Dhirendra Tripathi and Daniel Shvartsman Investing.com – Starting the year just under $49 a barrel, U.S. crude prices rose to a high of $85.41 in October and is poised to finish...
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Consumer Goods, Healthcare and Financials sectors propelled shares higher while losses in the Oil & Gas,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
